 | Vol. 10.01 – 20 January, 2025 |
| |
|
|
| After eight-days treatment of TGF-beta following by bFGF, cells entered into epithelium-mesenchymal transition and gave rise to smooth muscle cells. Epicardium could also integrate and invade into mouse heart with SNAI1 expression, and give birth to numerous cardiomyocyte-like cells. [Cell & Bioscience] |
|
|
|
 | PUBLICATIONSListed by the impact factor of the journal |
| |
|
|
| Researchers showed that the cysteine proteome of skeletal muscle functioned as a redox buffer in wild-type and murine dystrophin-deficient (mdx) muscle during eccentric contractions, but the buffer capacity in mdx muscle was significantly compromised by elevated basal protein oxidation. [Journal of Clinical Investigation] |
| |
|
|
| To better understand the role of MEGF10 in satellite cells, investigators overexpressed human multiple EGF domain protein 10 (MEGF10) in mouse H-2kb-tsA58 myoblasts and found that it inhibited fusion. [Journal of Muscle Research and Cell Motility] |
|
|
|
| Administering monoclonal antibodies to respectively neutralize TNF-α and IGF1 produced by CX3CR1+ cells from Marfan syndrome (MFS) patients greatly suppressed the cocultured MFS patient-specific induced pluripotent stem cell-derived vascular smooth muscle cell inflammation. [Journal of Clinical Investigation] |
|
|
|
| | Scientists revealed that hypoxia downregulated circCCNL2 expression, and overexpression of circCCNL2 attenuated pulmonary hypertension progression and inhibited the proliferation of pulmonary artery smooth muscle cell. [International Journal of Biological Macromolecules] |
|
|
|
| Researchers explored the effect of endogenous H2S/cystathionine γ-lyase pathway on the endothelin-1/endothelin type A receptor binding and its underlying mechanisms in the cellular and animal models of pulmonary arterial smooth muscle cell proliferation. [Cell Communication and Signaling] |
|
|
|
|
| The authors investigate how post-injury cellular signaling and energy metabolism are two pivotal points in zebrafish’s cardiomyocyte cell cycle re-entry and proliferation. [Current Cardiology Reports] |
|
|
|
|
| Santhera Pharmaceuticals announced that the National Institute for Health and Care Excellence (NICE) has issued positive Final Guidance that recommends AGAMREE® for use in the NHS in England, Wales, and Northern Ireland for the treatment of Duchenne muscular dystrophy in patients 4 years of age and older. [Santhera Pharmaceuticals] |
|
|
|
|
| Punta Cana, Dominican Republic |
|
|
|
|
|
| University of Leicester – Leicester, England, United Kingdom |
|
|
|
| University of California San Francisco – San Francisco, California, United States |
|
|
|
| Harvard University – Cambridge, Massachusetts, United States |
|
|
|
| Duke University – Durham, North Carolina, United States |
|
|
|
| Harvard University – Cambridge, Massachusetts, United States |
|
|
|
|